ZIRGAN dosing and administration for treatment of dendritic ulcers

ZIRGAN Dosing and Handling

ZIRGAN Dosing and Handling

ZIRGAN dosing and administration for treatment of dendritic ulcers
  • Recommended dosing regimen1:
    • One drop in the affected eye 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals
    • Followed by 1 drop 3 times per day for 7 days
  • ZIRGAN is supplied as 5 grams of a topical ophthalmic gel containing 0.15% of ganciclovir in a polycoated aluminum tube1. NDC number: 24208-535-35
  • There is no need for refrigeration (store between 59°F and 77°F). Do not freeze1
Accessing ZIRGAN

See if your patients are covered with Bausch + Lomb’s formulary tool.

Check our formulary tool
Help eligible patients save on ZIRGAN

Learn about a special savings offer from Bausch + Lomb.

See the details
Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.

Reference: 1. ZIRGAN [package insert]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2016.

 
Indication

ZIRGAN® (ganciclovir ophthalmic gel) 0.15% is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Safety Information
  • ZIRGAN is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Click here for full Prescribing Information for ZIRGAN.

ZIRGAN is a trademark of Laboratoires Théa Corporation used under license.

THIS WEBSITE IS INTENDED FOR U.S.
HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below: